Loading organizations...
§ Private Profile · Beijing, Beijing, China
AI medical imaging software developer assisting physicians in hospitals and medical institutions with disease screening, diagnosis, and treatment.
Infervision, based in Lyndhurst, New Jersey, USA, develops AI-driven medical imaging software for screening, diagnosis, intervention, treatment, and patient management. Its products, including InferRead® and InferOperate®, assist physicians in detecting cancers, infectious diseases, and cardiovascular conditions. The company's solutions are deployed in over 400 institutions across nearly 20 countries, serving healthcare providers including Peking Union Medical College Hospital. Infervision employs 51-100 individuals, holds FDA, CE, PMDA, and NMPA approvals, and by 2017, its AI processed 100,000 CT scans and 100,000 X-rays. Investors include Sequoia Capital China, with partners like GE Healthcare, Cisco, and Nvidia; Infervision was founded in 2016 by Kuan Chen. Its business model centers on sells on-premise AI software licenses and updates to hospitals and medical institutions, with deployments generating data for refinement.
Infervision has raised $186.4M across 2 funding rounds.
Infervision has raised $186.4M in total across 2 funding rounds.
Infervision has raised $186.4M across 2 funding rounds. Most recently, it raised $139.0M Series D in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 23, 2021 | $139M Series D | — | — | Announced |
| Mar 19, 2018 | $47.4M Series B | — | Advantech Capital, Genesis Capital, Hongshan Capital Group (Sequoia Capital China), Qiming Venture Partners, Xianghe Capital | Announced |
Infervision has raised $186.4M in total across 2 funding rounds.
Infervision's investors include Advantech Capital, Genesis Capital, Hongshan Capital Group (Sequoia Capital China), Qiming Venture Partners, Xianghe Capital.